Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 15;12:13825. doi: 10.1038/s41598-022-17338-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Improvement of survival and locomotor symptoms in Pla2g6^−/− mice following high-dose weekly semaglutide treatment. (A) Schematic of study design. Pla2g6^−/− mice received weekly IP administration of semaglutide (n = 6 per group, 0.5 µg/g, 0.25 μg/g or 0.15 μg/g) starting at 3 weeks old. Behavioural assays were performed for the high-dose treated group (0.5 μg/g/week) every week from week 5 to week 14. Tissue was collected at week 14. (B) Survival curve (n = 6 per experimental group); (C) examples of open field traces at weeks 9 and 12. All data are presented as mean (SEM); ordinary two-way ANOVA adjusted using Dunnett’s multiple comparisons test; p values reported in Table S4. (D) rotarod performance represented by latency to fall from accelerating rotarod (WT n = 6, Pla2g6^−/− n = 4; Pla2g6−/− Sema n = 4), and (E) time taken for mice to descend on the pole test (WT n = 6, Pla2g6^−/− n = 4; Pla2g6^−/− Sema n = 4). * indicates statistically significant difference between the relevant experimental group and WT controls; # indicates statistically significant difference between Pla2g6^−/− Sema mice and untreated Pla2g6^−/− controls.